Jae Hyun Jung, Gwan Gyu Song, Jae-Hoon Kim, Young Ho Seo, Sung Jae Choi1. 1. Korea University College of Medicine, Seoul, Korea Department of Internal Medicine, Division of Rheumatology, Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea. csjmd888@korea.ac.kr.
Abstract
BACKGROUND: Factor XIII plays an important role in the stabilization of the linkage between fibrins and in the pathophysiology of coronary artery disease (CAD). The association between factor XIII Val34Leu polymorphism and CAD risk remains controversial. METHODS: We conducted a meta-analysis of 36 studies involving 26,940 cases and 34,694 controls. Subgroup analyses were performed with division of data into disease (myocardial infarction [MI], CAD without MI), age, and sex. RESULTS: Factor XIII Val34Leu polymorphism was significantly associated with ove all CAD risk (odds ratio [OR] = 1.09, 95% confidence interval [CI] = 1.03-1.06, p = 0.004) and MI risk (OR = 1.15, 95% CI 1.07-1.25, p = 0.0003), but not with CAD without MI risk (OR = 1.00, 95% CI 0.87-1.15, p = 0.96). In the subgroup analysis by age and sex, there was no association between Val34Leu polymorphism and CAD. CONCLUSIONS: This meta-analysis found that factor XIII Val34Leu polymorphism was associated with CAD risk, especially MI, but not with CAD without MI. In addition, age and sex did not affect the relationship between factor XIII Val34Leu polymorphism and CAD risk.
BACKGROUND: Factor XIII plays an important role in the stabilization of the linkage between fibrins and in the pathophysiology of coronary artery disease (CAD). The association between factor XIII Val34Leu polymorphism and CAD risk remains controversial. METHODS: We conducted a meta-analysis of 36 studies involving 26,940 cases and 34,694 controls. Subgroup analyses were performed with division of data into disease (myocardial infarction [MI], CAD without MI), age, and sex. RESULTS: Factor XIII Val34Leu polymorphism was significantly associated with ove all CAD risk (odds ratio [OR] = 1.09, 95% confidence interval [CI] = 1.03-1.06, p = 0.004) and MI risk (OR = 1.15, 95% CI 1.07-1.25, p = 0.0003), but not with CAD without MI risk (OR = 1.00, 95% CI 0.87-1.15, p = 0.96). In the subgroup analysis by age and sex, there was no association between Val34Leu polymorphism and CAD. CONCLUSIONS: This meta-analysis found that factor XIII Val34Leu polymorphism was associated with CAD risk, especially MI, but not with CAD without MI. In addition, age and sex did not affect the relationship between factor XIII Val34Leu polymorphism and CAD risk.
Entities:
Keywords:
coagulation; coronary artery disease; factor XIII A Val34Leu; meta-analysis; myocardial infarction
Authors: Beata Sarecka-Hujar; Danuta Łoboda; Elżbieta Paradowska-Nowakowska; Krzysztof S Gołba Journal: J Clin Med Date: 2022-06-15 Impact factor: 4.964